| Literature DB >> 27867402 |
Marcela Soto-García1, Martha Rosales-Castro1, Gerardo N Escalona-Cardoso2, Norma Paniagua-Castro2.
Abstract
Quercus sideroxyla is a wood species whose bark has phenolic compound and should be considered to be bioactive; the hypoglycemic and genotoxic properties of Q. sideroxyla bark were evaluated in this study. Total phenolic compound was determined in crude extract (CE) and organic extract (OE). The OE has the highest amount of phenols (724.1 ± 12.0 GAE/g). Besides, both CE and OE demonstrated effect over the inhibition of α-amylase in vitro. Hypoglycemic activity was assessed by glucose tolerance curve and the area under curve (UAC); OE showed the highest hypoglycemic activity. In addition, diabetes was induced by streptozotocin (65 mg/kg) and the extracts (50 mg/kg) were administered for 10 days; OE showed hypoglycemic effect compared with diabetic control and decreased hepatic lipid peroxidation. Acute toxicity and genotoxicity were evaluated in CE; results of acute toxicity did not show any mortality. Besides, the comet assay showed that CE at a dose of 100 mg/kg did not show any genotoxic effect when evaluated at 24 h, whereas it induced slight damage at 200 mg/kg, with the formation of type 1 comets.Entities:
Year: 2016 PMID: 27867402 PMCID: PMC5102877 DOI: 10.1155/2016/4032618
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Concentration of phenolic compound and IC50 of α-amylase of CE of Q. sideroxyla bark extracts.
| Extract/standard | Total phenolic compound (GAE/g) | IC50 ( |
|---|---|---|
| CE | 551.0 ± 8.1a | 1979.3 ± 1.2a |
| OE | 724.1 ± 12.0b | 1703.3 ± 21.6b |
| Acarbose | — | 4030.1 ± 12.2c |
Each value represents the mean of n = 4 ± standard deviation. Different letters between groups in each column indicate a significant difference (p ≤ 0.05) assessed using the Fisher-LSD test.
Figure 1Glucose tolerance test in rats (a). Area under the glucose curve (b). p ≤ 0.05, significant difference compared with the control group. CE: crude extract at doses 200, 100, and 50 mg/kg; OE: organic extract at doses 50 and 25 mg/kg.
Blood glucose levels during the study period in Wistar rats.
| Group | Blood glucose (mg/dL) | |||
|---|---|---|---|---|
| Day 1 | Day 3 | Day 6 | Day 10 | |
| Control | 89.6 ± 5.1 | 92 ± 8.6 | 100.4 ± 7.5 | 91 ± 22.9 |
| Diabetic | 419.6 ± 49.6a | 442.2 ± 36.7a | 500 ± 3.1a | 500 ± 0a |
| Diabetic + CE50 | 462 ± 33.9a | 397.2 ± 61.2a | 465.5 ± 33.3a | 500 ± 0a |
| Diabetic + OE50 | 397 ± 10.4ab | 337.8 ± 34.6ab | 372.6 ± 7.5ab | 414.2 ± 62.5ab |
Data are expressed as mean ± standard deviation; n = 5. a: significant difference versus control group; b: versus diabetic group (p ≤ 0.05) in Fisher-LSD test. CE50: crude extract at dose 50 mg/kg; OE50: organic extract at dose 50 mg/kg.
Figure 2Hepatic lipid peroxidation assay in diabetic rats treated with CE50 and OE50 extracts during 10 days. a: significant difference versus control nondiabetic group; b: versus diabetic control group (p ≤ 0.05), Fisher-LSD test. CE: crude extract 50 mg/kg; OE: organic extract 50 mg/kg.
DNA damage according to the comet assay for the assessment of the genotoxicity of polyphenolic extract from Q. sideroxyla bark.
| Treatment | Comet class | ||||
|---|---|---|---|---|---|
| Total | 0 | 1 | 2 | 3 | |
| Blood sample (4 h) | |||||
| Negative control | 8 ± 4.8 | 92.5 ± 4.1 | 7 ± 3.5 | 0.5 ± 0.8 | 0 ± 0 |
| CPA (50 mg/kg) | 67.3 ± 6.9a | 66 ± 3.1a | 11.8 ± 3.3a | 11 ± 2.4a | 11.1 ± 1.0a |
| CE100 | 16.8 ± 6.3ab | 85.8 ± 4.9b | 12.1 ± 3.5a | 1.33 ± 0.8b | 0.66 ± 0.8 |
| CE200 | 39.5 ± 6.2abc | 69.8 ± 5.1a | 22.5 ± 6.0ab | 6 ± 2.09abc | 1.6 ± 0.8b |
| Blood sample (24 h) | |||||
| Negative control | 18.5 ± 6.9 | 88.6 ± 3.1 | 7.6 ± 3.3 | 3.1 ± 2.4 | 1.5 ± 1.04 |
| CPA (50 mg/kg) | 140.3 ± 21.2a | 37.5 ± 5.5a | 11 ± 6.2a | 25.2 ± 8.4a | 26.3 ± 6.3a |
| CE100 | 21.3 ± 6.1b | 85.5 ± 4.0b | 9.1 ± 0.7a | 3.3 ± 1.6b | 1.8 ± 1.4b |
| CE200 | 60 ± 14.3ab | 55.3 ± 5.9ab | 33.3 ± 3.4ab | 7.3 ± 4.0b | 4 ± 2.6b |
Each value represents the mean of n = 6 observations ± standard deviation. a: significant difference versus negative control group, b: versus CPA 50 mg/kg, and c: versus CE100; (p ≤ 0.05) LSD, comparing the treatments separately at 4 and 24 hours.
CPA: group treated with cyclophosphamide; CE100: group treated with crude extract at dose of 100 mg/kg; CE200: group treated with crude extract at dose of 200 mg/kg.
Figure 3Comet assay images in cell blood of mice (400x). (a) Comet type 0, (b) comet type 3, (c) comet type 1, and (d) comet types 1 and 2.